A leading Manhattan hospital, NYU Langone Health, has quietly dismantled its program providing gender-affirming care to minors, a decision driven by escalating threats to federal funding. The move marks a significant shift, leaving vulnerable young patients and their families scrambling for alternatives.
The hospital cited the recent departure of its medical director and a rapidly changing “regulatory environment” as the catalysts for this difficult choice. What was once a dedicated Transgender Youth Health Program now redirects to a broader “Gender & Sexuality Service,” focusing on exploration of identity rather than medical intervention.
This revised service offers mental health support to help children and families navigate gender identity, connecting them with appropriate resources. However, it no longer provides the same level of medical care, specifically hormone treatments and other interventions previously available.
Manhattan Borough President Brad Hoylman-Sigal expressed deep concern, understanding the hospital intends to halt crucial “gender-related care” for transgender youth. He warned of potentially devastating consequences for those affected, emphasizing the urgent need for continued access to treatment.
The decision wasn’t abrupt; NYU Langone ceased accepting new patients into the program last year, following an executive order from former President Donald Trump. This order aimed to restrict access to gender-affirming care for minors, labeling it as potential “chemical and surgical mutilation.”
Further pressure arrived in December with proposed rules from the Department of Health and Human Services (HHS) seeking to block Medicaid funding for hospitals performing gender-affirming procedures on individuals under 18. HHS Secretary Robert F. Kennedy Jr. framed the move as protecting children from “unsafe, irreversible practices.”
Adding another layer of complexity, a recent New York lawsuit resulted in a $1.6 million judgment for a woman who alleged she was pushed into a double mastectomy at age 16 without adequate mental health evaluation. While seemingly unrelated to NYU Langone, the case raises questions about the safeguards surrounding irreversible medical decisions for minors.
The implications of this verdict for other New York institutions providing transgender care remain unclear, but it undoubtedly adds to the growing scrutiny surrounding these procedures. The hospital system’s response to requests for comment has been limited.
The closure of NYU Langone’s program underscores a broader national battle over transgender healthcare, particularly for young people. It highlights the increasing political and legal pressures impacting medical institutions and the lives of those seeking care.
For the young patients now facing disruption in their treatment, the future is uncertain. Finding alternative care quickly will be paramount, and the responsibility for facilitating that transition now falls, in part, on the hospital system that has ended its services.
